Genotype 2

    1. G2 naïve NON-CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 99-100% SVR12 (ASTRAL-1 and 2)
      2. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 8 weeks à 99-100% SVR12 (ENDURANCE-2)

     

    1. G2 naïve COMPENSATED CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 99-100% SVR12 (ASTRAL-1 and 2)
      2. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 12 weeks à 99% SVR12 (EXPEDITION-1)

     

    1. G2 prior treatment failure to PEG + RBV NON-CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 99% SVR12 (ASTRAL- 2) AND 100% SVR12 (POLARIS-2)
      2. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 8 weeks à 98% SVR12 (SURVEYOR-II)

     

    1. G2 prior treatment failure to PEG + RBV COMPENSATED CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 99% SVR12 (ASTRAL- 2) AND 100% SVR12 (POLARIS-2)
      2. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 12 weeks à 100% SVR12 (EXPEDITION-1)

     

    1. G2 prior treatment failure to SOF + RBV NON-CIRRHOTIC OR COMPENSATED CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 97% SVR12 (POLARIS-4)
      2. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 12 weeks à 99% SVR12 (ENDURANCE-2) AND 100% SVR12 (EXPEDITION-1)

     

    1. G2 DECOMPENSATED CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily +/- RBV WBD for 12 weeks à 100% SVR12 [ASTRAL-4]

     

    SOF = Sofosbuvir [Solvaldi] – NS5B nucleotide analog polymerase inhibitor

    VEL = Velpatasvir [100 mg daily] – NS5A inhibitor

    Mavyret = Glecaprevir [300 mg] – NS3/4A protease inhibitor + Pibrentasvir [120 mg] – – NS5A inhibitor

Share on FacebookShare on Google+Share on LinkedInTweet about this on TwitterEmail this to someonePrint this page